Zejula with Zytiga and prednisone delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer ...

a partner and localizer of BRCA2 (PALB2), and BRCA1-interacting protein C-terminal helicase 1 (BRIP1), or through epigenetic modifications like promoter hypermethylation. Tumors exhibiting ...

A female patient with ovarian cancer harboring BRIP1 mutation showed a 7% tumor reduction at her first follow-up scan. Importantly, these results were observed at a dose level that is below the ...

and BRCA1-interacting protein 1 (BRIP1) result in Fanconi anaemia, and mono-allelic defects in BRCA2, BRCA1, PALB2 and BRIP1 result in a predisposition to breast cancer. Other human tumours are ...

As with the drug's 2023 approval in castration-resistant tumors, it's not clear if it works comparably in all homologous ...

Patients with stages I to III breast cancer who were seen at a single cancer center between 2010 and 2012, and who agreed to participate in research DNA banking, were included (N = 488). Personal and ...

Fanconi anemia is a rare inherited condition that can cause bone marrow failure, physical abnormalities, and an increased risk of some cancers. Symptoms include tiredness, infections, easy ...

Epidemiology and outcomes of disseminated intravascular coagulation in pancreatic cancer patients admitted with sepsis: Insights from a national database. This is an ASCO Meeting Abstract from the ...

DOYLESTOWN, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical ...